We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Universal Health Shares Drop 21% YTD: Should You Buy Now?
Read MoreHide Full Article
Key Takeaways
UHS shares are down 20.9% YTD as weaker volumes and ACA exchange pressures dent confidence.
UHS cut 2026 volume assumptions and lowered adjusted EBITDA guidance to $2.610-$2.717 billion.
UHS trades at 7.16X forward earnings after repurchasing $447.5 million of stock in first-half 2026.
Universal Health Services, Inc. (UHS - Free Report) shares have plunged 20.9% year to date, underperforming the industry’s growth of 12.4% and the S&P 500’s 12.3% rise, as investors have become much less confident about the quality and sustainability of future earnings. Meanwhile, peer Tenet Healthcare Corporation (THC - Free Report) has surged 35.2%, while HCA Healthcare, Inc. (HCA - Free Report) has lost 12.8%.
Price Performance – UHS, THC, HCA, Industry & S&P 500
Image Source: Zacks Investment Research
ACA/exchange exposure became a major concern early in the year. Those concerns are now showing up operationally. UHS said second-quarter exchange volumes fell about 15% YoY, shifting some patients toward self-pay. Also, volumes have been weaker than UHS originally expected.
First-quarter acute-care volumes were hurt by a weak flu and respiratory season and winter weather. By second quarter, management concluded that some softness was structural rather than just weather. It lowered 2026 same-facility growth assumptions to 1.5-2.5% for acute admissions, from 2-3%, and 1-2% for behavioral patient days, also from 2-3%. It lowered 2026 adjusted EBITDA guidance from $2.641-$2.789 billion to $2.610-$2.717 billion, cutting the midpoint by about $50 million.
As a result, analyst estimates have reset sharply. However, the estimates still indicate significant growth going forward.
Estimates for UHS
The Zacks Consensus Estimate for 2026 adjusted earnings stands at $23.08 per share, indicating year-over-year growth of 6.2%, followed by a projected 6.4% increase in 2027. Both witnessed one upward estimate revision over the past week, against one downward movement. Revenue estimates imply growth of 7.1% in 2026 and 5.3% in 2027.
UHS has exceeded earnings expectations in three of the past four quarters and missed once, delivering an average surprise of 8.3%.
Universal Health Services, Inc. Price, Consensus and EPS Surprise
The share price fall created a valuation cushion. The stock trades at a forward earnings multiple of 7.16X, below its five-year median of 10.77X and the industry average of 11.24X. Relative to peers, the valuation gap is even clearer. Tenet Healthcareand HCA Healthcaretrade at forward 12-month P/E ratios of 13.47X and 13.05X, respectively.
For a profitable hospital operator still growing earnings, that multiple implies the market is pricing in substantial reimbursement and operating problems. Even a modest normalization of the valuation multiple could produce meaningful upside. UHS now has a Value Score of A.
UHS shares trade below the average price target of $192.81, suggesting a potential upside of roughly 11.9%. While target estimates range widely from $290 to $166, reflecting varying risk assumptions, the overall outlook remains constructive.
Positives to Notice
The underlying business is still growing despite the bad headlines. First-half 2026 revenue increased 8.9%, and adjusted EPS rose from $10.19 to $11.60. Earnings estimates for both 2026 and 2027 also point to continued growth, although the expected growth is lower than previously anticipated.
UHS itself has been aggressively buying shares. The company repurchased $447.5 million of stock in the first half of 2026, including $320.3 million in the second quarter at an average price of about $169. It still had $977.6 million of repurchase authorization remaining at June 30.
UHS closed the $835 million Talkspace acquisition on Aug. 17. Strategically, the deal expands UHS beyond its traditional inpatient behavioral-health footprint into virtual therapy and psychiatry, giving it access to thousands of providers and a very large insured population. The potential to connect virtual care, outpatient treatment, inpatient facilities and post-discharge care within the same behavioral-health ecosystem can create massive opportunity for the company.
Conclusion
UHS’ steep share-price decline has created a compelling valuation opportunity, supported by continued earnings growth, aggressive share repurchases and the strategic addition of Talkspace. However, weaker volumes, ACA exchange pressures, reimbursement uncertainty and reduced growth expectations continue to cloud the near-term outlook.
With meaningful upside potential balanced by execution and policy risks, the risk-reward appears fairly balanced at current levels. Therefore, investors may prefer to wait for clearer operating improvement before investing. UHS currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
View the Zacks #1 Rank List
Image: Bigstock
Universal Health Shares Drop 21% YTD: Should You Buy Now?
Key Takeaways
Universal Health Services, Inc. (UHS - Free Report) shares have plunged 20.9% year to date, underperforming the industry’s growth of 12.4% and the S&P 500’s 12.3% rise, as investors have become much less confident about the quality and sustainability of future earnings. Meanwhile, peer Tenet Healthcare Corporation (THC - Free Report) has surged 35.2%, while HCA Healthcare, Inc. (HCA - Free Report) has lost 12.8%.
Price Performance – UHS, THC, HCA, Industry & S&P 500
ACA/exchange exposure became a major concern early in the year. Those concerns are now showing up operationally. UHS said second-quarter exchange volumes fell about 15% YoY, shifting some patients toward self-pay. Also, volumes have been weaker than UHS originally expected.
First-quarter acute-care volumes were hurt by a weak flu and respiratory season and winter weather. By second quarter, management concluded that some softness was structural rather than just weather. It lowered 2026 same-facility growth assumptions to 1.5-2.5% for acute admissions, from 2-3%, and 1-2% for behavioral patient days, also from 2-3%. It lowered 2026 adjusted EBITDA guidance from $2.641-$2.789 billion to $2.610-$2.717 billion, cutting the midpoint by about $50 million.
As a result, analyst estimates have reset sharply. However, the estimates still indicate significant growth going forward.
Estimates for UHS
The Zacks Consensus Estimate for 2026 adjusted earnings stands at $23.08 per share, indicating year-over-year growth of 6.2%, followed by a projected 6.4% increase in 2027. Both witnessed one upward estimate revision over the past week, against one downward movement. Revenue estimates imply growth of 7.1% in 2026 and 5.3% in 2027.
UHS has exceeded earnings expectations in three of the past four quarters and missed once, delivering an average surprise of 8.3%.
Universal Health Services, Inc. Price, Consensus and EPS Surprise
Universal Health Services, Inc. price-consensus-eps-surprise-chart | Universal Health Services, Inc. Quote
UHS’ Valuation
The share price fall created a valuation cushion. The stock trades at a forward earnings multiple of 7.16X, below its five-year median of 10.77X and the industry average of 11.24X. Relative to peers, the valuation gap is even clearer. Tenet Healthcareand HCA Healthcaretrade at forward 12-month P/E ratios of 13.47X and 13.05X, respectively.
For a profitable hospital operator still growing earnings, that multiple implies the market is pricing in substantial reimbursement and operating problems. Even a modest normalization of the valuation multiple could produce meaningful upside. UHS now has a Value Score of A.
UHS shares trade below the average price target of $192.81, suggesting a potential upside of roughly 11.9%. While target estimates range widely from $290 to $166, reflecting varying risk assumptions, the overall outlook remains constructive.
Positives to Notice
The underlying business is still growing despite the bad headlines. First-half 2026 revenue increased 8.9%, and adjusted EPS rose from $10.19 to $11.60. Earnings estimates for both 2026 and 2027 also point to continued growth, although the expected growth is lower than previously anticipated.
UHS itself has been aggressively buying shares. The company repurchased $447.5 million of stock in the first half of 2026, including $320.3 million in the second quarter at an average price of about $169. It still had $977.6 million of repurchase authorization remaining at June 30.
UHS closed the $835 million Talkspace acquisition on Aug. 17. Strategically, the deal expands UHS beyond its traditional inpatient behavioral-health footprint into virtual therapy and psychiatry, giving it access to thousands of providers and a very large insured population. The potential to connect virtual care, outpatient treatment, inpatient facilities and post-discharge care within the same behavioral-health ecosystem can create massive opportunity for the company.
Conclusion
UHS’ steep share-price decline has created a compelling valuation opportunity, supported by continued earnings growth, aggressive share repurchases and the strategic addition of Talkspace. However, weaker volumes, ACA exchange pressures, reimbursement uncertainty and reduced growth expectations continue to cloud the near-term outlook.
With meaningful upside potential balanced by execution and policy risks, the risk-reward appears fairly balanced at current levels. Therefore, investors may prefer to wait for clearer operating improvement before investing. UHS currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.